Published in J Cell Biochem on July 01, 2006
Transcriptional activity of androgen receptor is modulated by two RNA splicing factors, PSF and p54nrb. Mol Cell Biol (2007) 1.35
Compartmentalization of androgen receptor protein-protein interactions in living cells. J Cell Biol (2007) 1.25
Androgen receptor functional analyses by high throughput imaging: determination of ligand, cell cycle, and mutation-specific effects. PLoS One (2008) 1.13
A phosphomimetic mutation at threonine-57 abolishes transactivation activity and alters nuclear localization pattern of human pregnane x receptor. Drug Metab Dispos (2009) 1.07
Dynamic SUMOylation is linked to the activity cycles of androgen receptor in the cell nucleus. Mol Cell Biol (2012) 1.04
The activity of the androgen receptor variant AR-V7 is regulated by FOXO1 in a PTEN-PI3K-AKT-dependent way. Prostate (2012) 1.01
Nuclear proteins: finding and binding target sites in chromatin. Chromosome Res (2011) 1.01
Quantification of lipid droplets and associated proteins in cellular models of obesity via high-content/high-throughput microscopy and automated image analysis. Assay Drug Dev Technol (2009) 1.01
Heterodimerization with different Jun proteins controls c-Fos intranuclear dynamics and distribution. J Biol Chem (2010) 0.96
Bisphenol A affects androgen receptor function via multiple mechanisms. Chem Biol Interact (2013) 0.95
Profiling human androgen receptor mutations reveals treatment effects in a mouse model of prostate cancer. Mol Cancer Res (2008) 0.94
Visualizing the action of steroid hormone receptors in living cells. Nucl Recept Signal (2007) 0.93
AR inhibitors identified by high-throughput microscopy detection of conformational change and subcellular localization. ACS Chem Biol (2009) 0.90
Automated microscopy and image analysis for androgen receptor function. Methods Mol Biol (2011) 0.89
A multifunctional androgen receptor screening assay using the high-throughput Hypercyt flow cytometry system. Cytometry A (2008) 0.88
Androgen receptor mutations associated with androgen insensitivity syndrome: a high content analysis approach leading to personalized medicine. PLoS One (2009) 0.87
Clearance of the mutant androgen receptor in motoneuronal models of spinal and bulbar muscular atrophy. Neurobiol Aging (2013) 0.85
Androgen induces a switch from cytoplasmic retention to nuclear import of the androgen receptor. Mol Cell Biol (2013) 0.84
A comparative analysis of standard microtiter plate reading versus imaging in cellular assays. Assay Drug Dev Technol (2008) 0.84
Genome-wide footprinting: ready for prime time? Nat Methods (2016) 0.82
Antitumor effects of bladder cancer-specific adenovirus carrying E1A-androgen receptor in bladder cancer. Gene Ther (2012) 0.82
A versatile, bar-coded nuclear marker/reporter for live cell fluorescent and multiplexed high content imaging. PLoS One (2013) 0.79
New insights into the androgen-targeted therapies and epigenetic therapies in prostate cancer. Prostate Cancer (2011) 0.79
Effect of anabolic-androgenic steroids and glucocorticoids on the kinetics of hAR and hGR nucleocytoplasmic translocation. Mol Pharm (2010) 0.77
Steroid signaling activation and intracellular localization of sex steroid receptors. J Cell Commun Signal (2010) 0.77
Cell-based assays for screening androgen receptor ligands. Semin Reprod Med (2015) 0.76
Maximizing the quantitative accuracy and reproducibility of Förster resonance energy transfer measurement for screening by high throughput widefield microscopy. Methods (2013) 0.76
Transcriptional regulation of type 11 17β-hydroxysteroid dehydrogenase expression in prostate cancer cells. Mol Cell Endocrinol (2011) 0.75
Exploration of chromatic aberration for multiplanar imaging: proof of concept with implications for fast, efficient autofocus. Cytometry A (2009) 0.75
Advantages and Limitations of Androgen Receptor-Based Methods for Detecting Anabolic Androgenic Steroid Abuse as Performance Enhancing Drugs. PLoS One (2016) 0.75
Use of HCA in subproteome-immunization and screening of hybridoma supernatants to define distinct antibody binding patterns. Methods (2015) 0.75
Lentiviral vectors and protocols for creation of stable hESC lines for fluorescent tracking and drug resistance selection of cardiomyocytes. PLoS One (2009) 2.62
Neuropathogenic forms of huntingtin and androgen receptor inhibit fast axonal transport. Neuron (2003) 2.50
Colocalization of muscleblind with RNA foci is separable from mis-regulation of alternative splicing in myotonic dystrophy. J Cell Sci (2005) 2.31
SRC-3Delta4 mediates the interaction of EGFR with FAK to promote cell migration. Mol Cell (2010) 2.18
Role of SRC-1 in the promotion of prostate cancer cell growth and tumor progression. Cancer Res (2005) 2.14
Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer. Cancer Res (2006) 1.90
Androgen receptor action in hormone-dependent and recurrent prostate cancer. J Cell Biochem (2006) 1.85
Aurora-C kinase supports mitotic progression in the absence of Aurora-B. Cell Cycle (2009) 1.82
Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence. Cancer Res (2004) 1.75
Estrogen-receptor-alpha exchange and chromatin dynamics are ligand- and domain-dependent. J Cell Sci (2006) 1.72
Statistics of assay validation in high throughput cell imaging of nuclear factor kappaB nuclear translocation. Assay Drug Dev Technol (2005) 1.68
International Union of Pharmacology. LXV. The pharmacology and classification of the nuclear receptor superfamily: glucocorticoid, mineralocorticoid, progesterone, and androgen receptors. Pharmacol Rev (2006) 1.60
Aurora-C kinase is a novel chromosomal passenger protein that can complement Aurora-B kinase function in mitotic cells. Cell Motil Cytoskeleton (2004) 1.59
The role of extranuclear signaling actions of progesterone receptor in mediating progesterone regulation of gene expression and the cell cycle. Mol Endocrinol (2006) 1.56
Regulation of Bcl-2 expression by dihydrotestosterone in hormone sensitive LNCaP-FGC prostate cancer cells. J Urol (2003) 1.51
Class II (IIa)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl)pyrrolyl hydroxyamides. J Med Chem (2005) 1.51
The dynamic mobility of histone H1 is regulated by cyclin/CDK phosphorylation. Mol Cell Biol (2003) 1.47
Feed-forward inhibition of androgen receptor activity by glucocorticoid action in human adipocytes. Chem Biol (2012) 1.47
Histone deacetylation in epigenetics: an attractive target for anticancer therapy. Med Res Rev (2005) 1.46
Cyclin-dependent kinase activity is required for progesterone receptor function: novel role for cyclin A/Cdk2 as a progesterone receptor coactivator. Mol Cell Biol (2005) 1.41
Design, synthesis, and biological evaluation of sirtinol analogues as class III histone/protein deacetylase (Sirtuin) inhibitors. J Med Chem (2005) 1.40
Alteration of large-scale chromatin structure by estrogen receptor. Mol Cell Biol (2002) 1.36
Repressors of androgen and progesterone receptor action. J Biol Chem (2003) 1.35
Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells. Breast Cancer Res Treat (2009) 1.35
Peptidylarginine deiminase 2-catalyzed histone H3 arginine 26 citrullination facilitates estrogen receptor α target gene activation. Proc Natl Acad Sci U S A (2012) 1.35
Relaxin promotes prostate cancer progression. Clin Cancer Res (2007) 1.34
Phosphoproteome profiling of human skin fibroblast cells in response to low- and high-dose irradiation. J Proteome Res (2006) 1.33
Regulation of SRC-3 intercompartmental dynamics by estrogen receptor and phosphorylation. Mol Cell Biol (2007) 1.32
Decreased expression and androgen regulation of the tumor suppressor gene INPP4B in prostate cancer. Cancer Res (2011) 1.32
Intranuclear ataxin1 inclusions contain both fast- and slow-exchanging components. Nat Cell Biol (2002) 1.31
Androgen receptors in hormone-dependent and castration-resistant prostate cancer. Pharmacol Ther (2013) 1.28
Human progesterone receptor displays cell cycle-dependent changes in transcriptional activity. Mol Cell Biol (2005) 1.25
Regulation of inducible nitric oxide synthase by aggresome formation. Proc Natl Acad Sci U S A (2005) 1.23
A cell-based high-content screening assay reveals activators and inhibitors of cancer cell invasion. Sci Signal (2011) 1.20
Depth-varying density and organization of chondrocytes in immature and mature bovine articular cartilage assessed by 3d imaging and analysis. J Histochem Cytochem (2005) 1.20
Whole organism high-content screening by label-free, image-based Bayesian classification for parasitic diseases. PLoS Negl Trop Dis (2012) 1.19
Berardinelli-seip congenital lipodystrophy 2/seipin is a cell-autonomous regulator of lipolysis essential for adipocyte differentiation. Mol Cell Biol (2012) 1.17
Steroid receptor phosphorylation: Assigning function to site-specific phosphorylation. Biofactors (2009) 1.13
Androgen receptor functional analyses by high throughput imaging: determination of ligand, cell cycle, and mutation-specific effects. PLoS One (2008) 1.13
High throughput measurement of Ca²⁺ dynamics for drug risk assessment in human stem cell-derived cardiomyocytes by kinetic image cytometry. J Pharmacol Toxicol Methods (2012) 1.13
Androgen receptor coactivators and prostate cancer. Adv Exp Med Biol (2008) 1.12
Stat3 isoforms, alpha and beta, demonstrate distinct intracellular dynamics with prolonged nuclear retention of Stat3beta mapping to its unique C-terminal end. J Biol Chem (2007) 1.08
Androgen receptor signaling and vitamin D receptor action in prostate cancer cells. Prostate (2005) 1.06
Linear discriminant analysis-based estimation of the false discovery rate for phosphopeptide identifications. J Proteome Res (2008) 1.06
Growth factor-induced resistance to tamoxifen is associated with a mutation of estrogen receptor alpha and its phosphorylation at serine 305. Breast Cancer Res Treat (2009) 1.05
Identification of MicroRNAs that control lipid droplet formation and growth in hepatocytes via high-content screening. J Biomol Screen (2010) 1.05
Androgen receptor with elongated polyglutamine tract forms aggregates that alter axonal trafficking and mitochondrial distribution in motor neuronal processes. FASEB J (2002) 1.04
Target gene-specific regulation of androgen receptor activity by p42/p44 mitogen-activated protein kinase. Mol Endocrinol (2008) 1.03
A germline variation in the progesterone receptor gene increases transcriptional activity and may modify ovarian cancer risk. J Clin Endocrinol Metab (2004) 1.03
Two-dimensional liquid chromatography system for online top-down mass spectrometry. Proteomics (2010) 1.03
Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression. Int J Oncol (2012) 1.02
Coactivator selective regulation of androgen receptor activity. Steroids (2009) 1.02
The activity of the androgen receptor variant AR-V7 is regulated by FOXO1 in a PTEN-PI3K-AKT-dependent way. Prostate (2012) 1.01
Enhanced top-down characterization of histone post-translational modifications. Genome Biol (2012) 1.01
Quantification of lipid droplets and associated proteins in cellular models of obesity via high-content/high-throughput microscopy and automated image analysis. Assay Drug Dev Technol (2009) 1.01
Identification of a novel mitotic phosphorylation motif associated with protein localization to the mitotic apparatus. J Cell Sci (2007) 1.00
Mutation of SOD1 in ALS: a gain of a loss of function. Hum Mol Genet (2007) 1.00
p53 Is required for 1,25-dihydroxyvitamin D3-induced G0 arrest but is not required for G1 accumulation or apoptosis of LNCaP prostate cancer cells. Endocrinology (2003) 1.00
Functional proteometrics for cell migration. Cytometry A (2006) 0.99
Androgen receptor splice variants are resistant to inhibitors of Hsp90 and FKBP52, which alter androgen receptor activity and expression. Steroids (2013) 0.99
1Alpha,25-dihydroxyvitamin D3 reduces c-Myc expression, inhibiting proliferation and causing G1 accumulation in C4-2 prostate cancer cells. Endocrinology (2009) 0.99
Vitamin D and prostate cancer. Exp Biol Med (Maywood) (2004) 0.99
Coactivators enable glucocorticoid receptor recruitment to fine-tune estrogen receptor transcriptional responses. Nucleic Acids Res (2013) 0.98
Mind perception: real but not artificial faces sustain neural activity beyond the N170/VPP. PLoS One (2011) 0.98
Synthesis and biological validation of novel synthetic histone/protein methyltransferase inhibitors. ChemMedChem (2007) 0.97
Mechanistic differences in the activation of estrogen receptor-alpha (ER alpha)- and ER beta-dependent gene expression by cAMP signaling pathway(s). J Biol Chem (2003) 0.97
Vitamin D and prostate cancer. J Androl (2002) 0.97
Activation of estrogen receptor-alpha by E2 or EGF induces temporally distinct patterns of large-scale chromatin modification and mRNA transcription. PLoS One (2008) 0.97
Reduced intranuclear mobility of APL fusion proteins accompanies their mislocalization and results in sequestration and decreased mobility of retinoid X receptor alpha. Mol Cell Biol (2004) 0.96
Developmental expression and gene regulation of insulin-like 3 receptor RXFP2 in mouse male reproductive organs. Biol Reprod (2007) 0.96
The functional consequences of cross-talk between the vitamin D receptor and ERK signaling pathways are cell-specific. J Biol Chem (2004) 0.96
Cyclin dependent kinase 2 and the regulation of human progesterone receptor activity. Steroids (2007) 0.95
Small molecule inhibitors of histone arginine methyltransferases: homology modeling, molecular docking, binding mode analysis, and biological evaluations. J Med Chem (2007) 0.95
Suppression of relaxin receptor RXFP1 decreases prostate cancer growth and metastasis. Endocr Relat Cancer (2010) 0.95
Plasma membrane assays and three-compartment image cytometry for high content screening. Assay Drug Dev Technol (2007) 0.95
Parathyroid hormone-related protein regulates cell survival pathways via integrin alpha6beta4-mediated activation of phosphatidylinositol 3-kinase/Akt signaling. Mol Cancer Res (2009) 0.94
High-throughput proteomics. Annu Rev Anal Chem (Palo Alto Calif) (2014) 0.94
Resistance to antiestrogen arzoxifene is mediated by overexpression of cyclin D1. Mol Endocrinol (2009) 0.94
A live cell, image-based approach to understanding the enzymology and pharmacology of 2-bromopalmitate and palmitoylation. Methods Enzymol (2006) 0.94
c-Jun N-terminal kinase contributes to aberrant retinoid signaling in lung cancer cells by phosphorylating and inducing proteasomal degradation of retinoic acid receptor alpha. Mol Cell Biol (2005) 0.93
The hinge region of the human estrogen receptor determines functional synergy between AF-1 and AF-2 in the quantitative response to estradiol and tamoxifen. J Cell Sci (2010) 0.93
Homeostatic levels of SRC-2 and SRC-3 promote early human adipogenesis. J Cell Biol (2011) 0.93
High-resolution, high-throughput microscopy analyses of nuclear receptor and coregulator function. Methods Enzymol (2006) 0.93
Digital differential interference contrast autofocus for high-resolution oil-immersion microscopy. Cytometry A (2008) 0.93
Metabolomic profiling identifies biochemical pathways associated with castration-resistant prostate cancer. J Proteome Res (2013) 0.92
Role of insulin-like growth factor binding proteins in 1alpha,25-dihydroxyvitamin D(3)-induced growth inhibition of human prostate cancer cells. Prostate (2005) 0.91
Inhibition of proliferation and induction of apoptosis by 25-hydroxyvitamin D3-3beta-(2)-Bromoacetate, a nontoxic and vitamin D receptor-alkylating analog of 25-hydroxyvitamin D3 in prostate cancer cells. Clin Cancer Res (2004) 0.91
Dual roles for the phosphatase PPM1D in regulating progesterone receptor function. J Biol Chem (2005) 0.91